Juno Therapeutics at the 59th ASH Annual Meeting and Exposition

Atlanta, Georgia l December 9 – 12, 2017
Booth #523

 

 

TRANSCEND

All presentations presented at Georgia World Congress Center

 

Saturday, December 9, 2017
2:00 PM – 3:30 PM, 2:00 presentation, Bldg C, Lvl 1, C101 Aud

Abstract #: 193 / First Author: T. Siddiqi

Patient Characteristics and Pre-Infusion Biomarkers of Inflammation Correlate with Clinical Outcomes after Treatment with the Defined Composition, CD19-Targeted CAR T Cell Product, JCAR017

Session Type: Oral Abstract

627: Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)—Results from Retrospective/Observational Studies: Predicting Efficacy and Safety of CAR-T cells and Checkpoint Blockade

 

Saturday, December 9, 2017
2:00 PM – 3:30 PM, 2:15 presentation,  Bldg C, Lvl 1, C101 Aud

Abstract #: 194 / First Author: C. Swanson (H. Stern presenting)

Predicting Clinical Response and Safety of JCAR017 in B-NHL Patients: Potential Importance of Tumor Microenvironment Biomarkers and CAR T-Cell Tumor Infiltration

Session Type: Oral Abstract

627: Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)—Results from Retrospective/Observational Studies: Predicting Efficacy and Safety of CAR-T cells and Checkpoint Blockade

 

Saturday, December 9, 2017
5:30 PM – 7:30 PM, Bldg A, Lvl 1, Hall A2

Abstract #: 1552 / First Author: D. Maloney

Preliminary Safety Profile of the CD19-Directed Defined Composition CAR T Cell Product JCAR017 in Relapsed/Refractory Aggressive B-NHL Patients: Potential for Outpatient Administration

Session Type: Poster

626: Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)—Results from Prospective Clinical Trials: Poster I

 

Sunday, December 10, 2017
6:00 PM – 8:00 PM, Bldg A, Lvl 1, Hall A2

Abstract #: 2835 / First Author: M. Heipel (C. Sutherland presenting)

Pharmacokinetic, Pharmacodynamic and Blood Analytes Associated with Clinical Response and Safety in Relapsed/Refractory Aggressive B-NHL Patients Treated with JCAR017

Session Type: Poster

626: Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)—Results from Prospective Clinical Trials: Poster II

 

Monday, December 11, 2017
6:00 PM – 8:00 PM, Bldg A, Lvl 1, Hall A2

Abstract #: 581 / First Author: J. Abramson

High Durable CR Rates in R/R Aggressive B-NHL Treated with JCAR017 (TRANSCEND NHL 001): Defined Composition CD19-Directed CAR T Cell Product Allows for Dose Finding and Definition of Pivotal Cohort

Session Type: Oral Abstract

626. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas) — Results from Prospective Clinical Trials: Immune-Based Therapeutic Approaches

 

Monday, December 11, 2017
6:00 PM – 8:00 PM, Bldg A, Lvl 1, Hall A2

Abstract #: 4471 / First Author: C. Ramsborg

JCAR017 is a Defined Composition CAR T Cell Product with Product and Process Controls That Deliver Precise Doses of CD4 and CD8 CAR T Cell to Patients with NHL

Session Type: Poster

711: Cell Collection and Processing: Poster III

 

 

 

BCMA

All presentations presented at Georgia World Congress Center

 

Saturday, December 9, 2017
5:30 PM – 7:30 PM, Bldg A, Lvl 1, Hall A2

Abstract #: 1813 / First Author: K. Harrington

Development of JCARH125: Optimization of a fully human anti-BCMA CAR for use in the treatment of Multiple Myeloma

Session Type: Poster

653: Myeloma: Therapy, excluding Transplantation: Poster I

 

Saturday, December 9, 2017
5:30 PM – 7:30 PM, Bldg A, Lvl 1, Hall A2

Abstract #: 1791 / First Author: Q. Vong

Inhibiting TGFβ signaling in CAR T-cells may significantly enhance efficacy of tumor immunotherapy

Session Type: Poster

Abstract 652: Myeloma: Pathophysiology and Pre-Clinical Studies, excluding Therapy: Poster I

 

Saturday, December 9, 2017
5:30 PM – 7:30 PM, Bldg A, Lvl 1, Hall A2

Abstract #: 1794 / First Author: M. Works

Lenalidomide Enhances Anti-BCMA Chimeric Antigen Receptor T cell Function Against Multiple Myeloma

Session Type: Poster

652: Myeloma: Pathophysiology and Pre-Clinical Studies, excluding Therapy: Poster I

 

 

Investor Relations:

Nicole Keith, 206-566-5521
nikki.keith@junotherapeutics.com

 

Media:

Christopher Williams, 206-566-5660
chris.williams@junotherapeutics.com